• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca's Full Year and Q4 2024 results

    2/6/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively

    AstraZeneca:

    Revenue and EPS summary

     

     

    FY 2024

    % Change

    Q4 2024

    % Change

    $m

    Actual

    CERi

    $m

    Actual

    CER

    - Product Sales

    50,938

    16

    19

    13,362

    18

    19

    - Alliance Revenue

     

    2,212

    55

    55

    714

    68

    69

    - Collaboration Revenue

    923

    56

    54

    815

    >2x

    >2x

    Total Revenue

     

    54,073

    18

    21

    14,891

    24

    25

    Reported EPS

    $4.54

    18

    29

    $0.97

    56

    71

    Coreii EPS

    $8.21

    13

    19

    $2.09

    44

    49

    Financial performance for FY 2024 (Growth numbers at constant exchange rates)

    Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered medicines (Alliance Revenue) and the achievement of sales-based milestones (Collaboration Revenue)

    Total Revenue growth from Oncology was 24%, CVRM 20%, R&I 25%, V&I 8% and Rare Disease 16%

    Core EPS increased 19% to $8.21

    Second interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Dividend to be further increased in FY 2025

    Guidance for FY 2025: Total Revenue is expected to increase by a high single-digit percentage and Core EPS is expected to increase by a low double-digit percentage, both at CER

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

    "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025.

    This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80 billion Total Revenue by the end of the decade. In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines.

    We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth well beyond 2030, many of which have now entered pivotal trials."

    Key milestones achieved since the prior results announcement

    Positive read-outs for Truqap in combination with abiraterone and androgen deprivation therapy in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (CAPItello-281) and Tagrisso with or without chemotherapy in resectable early-stage EGFRm NSCLC (NeoADAURA)

    US approvals for Imfinzi in limited-stage small cell lung cancer (ADRIATIC), Calquence in combination with bendamustine and rituximab in mantle cell lymphoma (ECHO), Datroway (datopotamab deruxtecan) in HR+ HER2- metastatic breast cancer (TROPION-Breast01) and Enhertu in chemotherapy-naïve HER2-low and -ultralow metastatic breast cancer (DESTINY-Breast06). EU approvals for Tagrisso in unresectable EGFRm NSCLC (LAURA) and Kavigale for prevention of COVID-19 (SUPERNOVA). Japan approvals for Imfinzi in endometrial cancer (DUO-E), Lynparza plus Imfinzi in pMMR endometrial cancer (DUO-E), Calquence tablet formulation in chronic / small lymphocytic leukaemia, Datroway in HR+ HER2- metastatic breast cancer, Fasenra in EGPA (MANDARA) and Kavigale for prevention of COVID-19. China approvals for Lynparza in gBRCAm HER2- early breast cancer (OlympiA), Orpathys in locally advanced or metastatic MET Exon 14 NSCLC (NCT04923945)

    Guidance

    The Company issues its Total Revenue and Core EPS guidance for FY 2025 at CER, based on the average foreign exchange rates through 2024.

     

    Total Revenue is expected to increase by a high single-digit percentage

    Core EPS is expected to increase by a low double-digit percentage

     

    The Core Tax rate is expected to be between 18-22%

    The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

    Currency impact

    If foreign exchange rates for February 2025 to December 2025 were to remain at the average rates seen in January 2025, it is anticipated that Total Revenue in FY 2025 would incur a low single-digit percentage adverse impact compared to the performance at CER, and Core EPS would incur a mid-single-digit percentage adverse impact. The Company's foreign exchange rate sensitivity analysis is provided in Table 17.

    Capital allocation

    In FY 2025, the Company intends to increase the annual dividend declared to $3.20 per share. The Company also expects to increase capital expenditureiii by approximately 50%, driven by manufacturing expansion projects and investment in IT systems, to support portfolio growth and build capacity for transformative technologies.

    China

    In relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $0.9 million. To the best of AstraZeneca's knowledge, the importation taxes referred to in the Appraisal Opinion relate to Imfinzi and Imjudo. A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable. AstraZeneca continues to fully cooperate with the Chinese authorities.

    In December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International, which encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. Iskra succeeds Leon Wang who is on extended leave from the Company while under investigation in China.

    Table 1: Key elements of Total Revenue performance in Q4 2024

    % Change

    Revenue type

     

    $m

    Actual %

    CER %

     

     

    Product Sales

    13,362

    18

    19

     

     

    Alliance Revenue

     

    714

    68

    69

     

    $392m Enhertu (Q4 2023: $281m)

    $133m Tezspire (Q4 2023: $80m)

    $161m Beyfortus (Q4 2023: $41m)

    Collaboration Revenue

    815

    >2x

    >2x

     

    $600m Lynparza (Q4 2023: $245m)

    $111m Beyfortus (Q4 2023: $27m)

    $100m Koselugo (Q4 2023: nil)

    Total Revenue

     

    14,891

    24

    25

     

     

    Therapy areas

    $m

    Actual %

    CER %

     

     

    Oncology

    6,344

    27

    29

     

    Tagrisso up 20% (21% at CER), Calquence up 20%, Enhertu up 48% (54% at CER)

    CVRM

    3,138

    16

    17

     

    Farxiga up 21% (22% at CER), Lokelma up 35%

    R&I

     

    2,127

    27

    28

     

    Breztri up 29%. Saphnelo up 65%, Tezspire up 86% (85% at CER), Symbicort up 31% (33% CER)

    V&I

     

    651

    58

    55

     

    Beyfortus Total Revenue up >3x

    Rare Disease

     

    2,377

    21

    22

     

    Ultomiris up 32% (33% at CER), partially offset by decline in Soliris of 24% (22% at CER), Strensiq up 38% (37% at CER) and Koselugo up >3x

    Other Medicines

     

    254

    (7)

    (6)

     

     

    Total Revenue

     

    14,891

    24

    25

     

     

    Regions

     

    $m

    Actual %

    CER %

     

     

    US

    6,532

    28

    28

     

    Product Sales up 25%

    Emerging Markets

     

    3,134

    13

    19

     

     

    - China

    1,364

    (1)

    (3)

     

    Decline primarily due to low rates of seasonal respiratory viral infections, and impact from year-end hospital budget dynamics

    - Ex-China Emerging Markets

     

    1,770

    26

    42

     

     

    Europe

     

    3,948

    37

    35

     

    Product Sales up 20% (18% at CER)

    Established RoW

     

    1,277

    1

    2

     

     

    Total Revenue

     

    14,891

    24

    25

     

     

    Key alliance medicines

    Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted to $3,754m in FY 2024 (FY 2023: $2,566m)

    Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $1,219m in FY 2024 (FY 2023: $653m)

    Table 2: Key elements of financial performance in Q4 2024

    Metric

    Reported

    Reported

    change

    Core

    Core

    change

     

    Commentsiv

    Total Revenue

    $14,891m

    24% Actual

    25% CER

    $14,891m

    24% Actual

    25% CER

     

    See Table 1 and the Total Revenue section of this document for further details

    Product Sales Gross Margin

    80%

    Stable Actual

    +1pp CER

    79%

    -1pp Actual

    Stable CER

     

    Variations in Product Sales Gross Margin can be expected between periods, due to product seasonality, foreign exchange fluctuations and other effects

    R&D

    expense

    $4,677m

    52% Actual

    52% CER

    $3,573m

    23% Actual

    22% CER

     

    Increased investment in the pipeline

    Core R&D-to-Total Revenue ratio of 24%

    (Q4 2023: 24%)

    Reported R&D includes $753m impairment recorded against the vemircopan (ALXN2050) intangible asset

    SG&A expense

    $5,410m

    1% Actual

    1% CER

    $4,275m

    6% Actual

    7% CER

     

    Market development for recent launches and pre-launch activities

    Core SG&A-to-Total Revenue ratio of 29%

    (Q4 2023: 34%)

    Other operating income and expensev

    $100m

    -7% Actual

    -6% CER

    $101m

    -7% Actual

    -6% CER

     

     

    Operating Margin

    14%

    +3pp Actual

    +4pp CER

    28%

    +5pp Actual

    +6pp CER

     

    See commentary above on Gross Margin, R&D, SG&A and Other operating income and expense

    Net finance expense

    $365m

    9% Actual

    8% CER

    $310m

    20% Actual

    20% CER

     

    Recent debt issued at higher interest rates

    Decrease in interest income

    Higher level of Net debt

    Tax rate

    10%

    +17pp Actual

    +15pp CER

    16%

    +7pp Actual

    +7pp CER

     

    Variations in the tax rate can be expected between periods

    EPS

    $0.97

    56% Actual

    71% CER

    $2.09

    44% Actual

    49% CER

     

    Further details of differences between Reported and Core are shown in Table 12

    Table 3: Pipeline highlights since prior results announcement

    Event

    Medicine

    Indication / Trial

    Event

    Regulatory approvals and other regulatory actions

    Tagrisso

    EGFRm NSCLC (Stage III

    unresectable) (LAURA)

    Regulatory approval (EU, CN)

    Imfinzi

    Limited-stage SCLC (ADRIATIC)

    Regulatory approval (EU)

    Imfinzi

    Advanced endometrial cancer

    Regulatory approval (JP)

    Calquence

    Tablets for chronic lymphocytic leukaemia

    Regulatory approval (JP)

    Calquence

    Mantle cell lymphoma (1st-line) (ECHO)

    Regulatory approval (US)

    Lynparza + Imfinzi

    Advanced endometrial cancer with mismatch repair proficiency

    (DUO-E)

    Regulatory approval (JP)

    Lynparza

    gBRCAm HER2- eBC (OlympiA)

    Regulatory approval (CN)

    Enhertu

    HR+ HER2-low and -ultralow mBC

    (DESTINY-Breast06)

    Regulatory approval (US)

    Datroway

    HR+ HER2- mBC (TROPION-Breast01)

    Regulatory approval (JP, US)

    Orpathys

    MET exon 14 skipping altered NSCLC (NCT04923945)

    Regulatory approval (CN)

    Fasenra

    EGPA (MANDARA)

    Regulatory approval (JP)

    Kavigale

    Prevention of COVID-19 (SUPERNOVA)

    Regulatory approval (EU, JP)

     

     

     

    Regulatory submissions or acceptances*

    Imfinzi

    Muscle-invasive bladder

    cancer (NIAGARA)

    Regulatory submission (US, JP)

    Imfinzi + Imjudo

    NSCLC (1st-line) (POSEIDON)

    Regulatory submission (CN)

    Calquence

    Chronic lymphocytic leukaemia (1st-line) (AMPLIFY)

    Regulatory submission (EU)

    Datroway

    EGFRm NSCLC (later line) (TROPION-Lung05)

    Regulatory submission (US)

    Tezspire

    Severe uncontrolled asthma (NAVIGATOR/

    DIRECTION)

    Regulatory submission (CN)

    Koselugo

    Neurofibromatosis type 1 adult (KOMET)

    Regulatory submission (EU, JP)

     

     

     

    Phase III / registrational data readouts and other developments

    Tagrisso

    Resectable early-stage EGFRm NSCLC (NeoADAURA)

    Primary endpoint met

    Truqap

    PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (CAPItello-281)

    Primary endpoint met

     

     

     

     

    *US, EU and China regulatory submission denotes filing acceptance

    Other pipeline updates

    In January 2025, the vemircopan (ALXN2050) Phase II development programme was terminated. The decision was based on safety and efficacy data from Phase II trials.

    Upcoming pipeline catalysts

    For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html.

    Sustainability highlights

    The Company convened an event on health equity for investors and analysts in November that detailed AstraZeneca's health equity strategy, which is embedded from the Company's science through to healthcare delivery and community engagement.

    At the end of 2024, the Company's cumulative reduction in Scope 1 and 2 greenhouse gas (GHG) emissions was 77.5% from the 2015 baseline.

    Conference call

    A conference call and webcast for investors and analysts will begin today, 6 February 2025, at 11:00 UK time. Details can be accessed via astrazeneca.com.

    Reporting calendar

    The Company intends to publish its Q1 2025 results on 29 April 2025.

    To read AstraZeneca's Full Year and Q4 2024 Financial Results press release in full, click here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250205200649/en/

    Global Media Relations team

    [email protected]

    +44 (0)1223 344 800

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

      Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI versus maintenance

      5/2/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/2/25 9:38:38 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care